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Summary This prospective, open-label study evaluated the efficacy and safety of
adjunctive levetiracetam (LEV) in Korean adults with uncontrolled partial epilepsy.
Study patients had to have an average of at least 1 and not more than 14 partial
seizures per month (averaged over a 3-month historical baseline) despite the use of
one or two AEDs. Patients initially received LEV 1000 mg/day (administered bid) and
could increase to 2000 mg/day after 2 weeks, and to 3000 mg/day after another 2
weeks, to obtain adequate seizure control. During the 12-week maintenance period,
the dose of LEV could be increased or decreased once if seizure control was
insufficient or tolerability warranted, respectively. Seizure count and adverse events
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(AEs) were recorded by patients. Global evaluation scale (GES) and quality of life
(QOLIE-31) were also evaluated.
A total of 100 patients were enrolled and 92 patients completed the study. The
median percent reduction in weekly seizure frequency over the treatment period was
43.2%. The 50% and 75% responder rates were 45.4% and 36.1%, respectively.
Seizure freedom throughout the 16-week treatment period was observed in 17
patients. On investigator’s GES, 81 patients were considered improved, with 41
patients showing marked improvement. Most QOLIE-31 scales improved significantly.
Treatment-emergent AEs were reported in 59 patients. Three most common AEs were
somnolence (36%), dizziness (12%), and headache (8%).
Adjunctive LEV therapy was effective and well-tolerated in Korean adults with
refractory partial epilepsy.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Levetiracetam (LEV) is a newer antiepileptic drug
(AED) that has been approved as an adjunctive
treatment in adults with partial epilepsy in more
than 50 countries. LEV has close to ideal pharma-
cokinetic characteristics, that include high oral
bioavailability, linear pharmacokinetics, low plasma
protein binding, primary excretion unchanged in
urine, and no known clinically significant drug-drug
interactions.1 LEV has a unique pharmacological
activity profile in animal models of seizures and
epilepsy.2 The discovery of SV2A as the binding site
of LEV in the brain has proven it possesses a mechan-
ism of action distinct from other AEDs.3 Thus, its
clinical efficacy and tolerability profiles may be
different from other AEDs.
LEV efficacy was established in double-blind,
placebo-controlled trials4—6 and effectiveness by
indirect comparisons based on meta-analysis which
suggest that add-on therapy with LEV has a favour-
able responder and/or withdrawal rate relative to
several new AEDs in patients with partial epilepsy.7
Multicentre, short-term, open-label, single-arm,
add-on trials of LEV also demonstrated its efficacy
and safety.8—10 LEV seems to be promising in long-
term treatment. Recently, Depondt et al.11 reported
experience with LEV treatment of 811 patients with
refractory epilepsy including generalized epilepsy
and estimated the 3 year retention rate at 58%.
Furthermore, long-term, add-on trials of LEV
showed seizure freedom for 6 months in 10—30%
of patients.11—16
The present study, conducted in Korea, further
assessed the efficacy and safety of LEV as add-on
therapy in patients suffering from partial seizures
not adequately controlled despite treatment with
up to two other AEDs. The impact of LEV on health-
related quality of life was also assessed. The pro-
tocol used an open-label methodology, very similar
to routine clinical practice regarding inclusion cri-
teria and dose escalation.Methods
Study population
Patients 18 years or older with partial seizures,
whether or not secondarily generalized, were eligi-
ble for enrolment. Patients must have presented
with an average of at least 1 and not more than 14
partial seizures per month (averaged over a 3-month
period preceding study entry) despite the use of one
or two AEDs. Partial seizures were classified accord-
ing to the Commission on the Classification and
Terminology of the International League against
Epilepsy.17 Patients were allowed one but not more
than two concomitant AEDs at the time of study
entry, with benzodiazepines being considered as an
AED if taken on a daily basis for any indication. The
AED regimen was required to have been stable for at
least 4 weeks prior to study entry. Patients with
mild-to-moderate renal impairment were eligible
with appropriate dose adjustment. Patients were
excluded if they had conditions expected to unduly
complicate management or evaluation. This
included serious psychiatric disorder within the past
5 years, uncountable seizures or history of convul-
sive status epilepticus within the last 5 years, pre-
sence of known pseudoseizures within the last year,
progressive degenerative neurological disease, pre-
vious exposure to LEV, participation in another clin-
ical study with investigational drug or device within
12 weeks of the selection visit, history of question-
able compliance to schedule visit or medication
intake, pregnant or lactating females and females
of childbearing potential unwilling to utilize a medi-
cally acceptable birth control method, and visual
field defect relevant to vigabatrin as a previous or
concomitant AED.
Study design
This therapeutic confirmatory Phase III open-label,
single-arm study of patients with partial seizures
404 K. Heo et al.began with a 3-month historical baseline period
followed by a 16-week treatment period in 9 Korean
centres. Prior to initiation, the study was approved
by Institutional Review Board of each centre. It was
conducted according to ICH guidelines and the
Declaration of Helsinki.
The study was divided into an up-titration per-
iod (first 4 weeks) and a maintenance period (last
12 weeks) as shown in Fig. 1. At visit 1 (week 0),
investigators obtained patients’ written informed
consent, collected demographic data and medi-
cal/surgical histories, and performed physical and
neurological examinations, including vital signs
and body mass. During the 4-week up-titration
period, patients initially received LEV 1000 mg/
day (V1) (administered bid). The dose could be
increased to 2000 mg/day after 2 weeks (V2) and
to 3000 mg/day after an additional 2 weeks (V3) at
the discretion of the investigator if it was clini-
cally necessary to achieve maximum benefit. Dur-
ing the 12-week maintenance period LEV dose
could be increased at V4 (week 10) in patients
who were receiving either of the two lower doses
if seizure control was insufficient, and decreased
on a single occasion in patients who were receiv-
ing either of the two higher doses if poorly toler-
ated.
At week 16, patients made a fifth and final visit on
completion of the study, at which time final data
were collected. At this time, patients were also
given the opportunity to continue treatment in a
separate Named Patient Program as long-term fol-
low-up. Those who elected not to continue had their
dose gradually reduced and were seen again 2 weeks
after the last dose.
Patients recorded the date, number, and type of
seizures on a daily record card; each investigatorFigure 1 Stucoded the seizures experienced by his or her
patients. Adverse events (AEs) were recorded at
each visit based on spontaneous patient reports,
investigator observation, responses to a standard
question asked by the investigator, and events
recorded on the patient daily record card.
Prior and concomitant therapy
The history of previous AEDs was investigated. For
the purposes of the study evaluation, the patient’s
concomitant AEDs had to remain constant during the
study, except when medically needed. Additional
medication could be prescribed for the well-being of
the patient; however, medication (other than AEDs)
affecting the central nervous system was to be
avoided unless the patient had been on a stable
dose for at least the last 6 months before the first
visit. Concomitant medication remained at the
same stable dose throughout the study.
Efficacy and safety measurements
Efficacy end points were based on the frequency of
seizures during the 16-week treatment period (titra-
tion and maintenance) compared with the 3-month
baseline period as well as retention rate. The pri-
mary efficacy variables were the percent reduction
from baseline in seizure frequency per week and the
retention rate at week 16, defined as the number of
subjects still treated with LEVat the end of 16-week
treatment period divided by the number of patients
in the intent-to-treat (ITT) population. Other effi-
cacy variables included the absolute reduction in
the frequency of partial seizures per week, the
responder rates and the number of seizure-
free patients. For patients who did not completedy design.
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Table 1 Baseline demographic and clinical character-
istics of the 100 enrolled patients
Parameter Value
Age, years (mean  S.D.) a 35.3  11.7
Gender, male (%) 52.0%
Body weight, kg (mean  S.D.) 63.7  12.5
Height, kg (mean  S.D.) 165.2  8.3
Body mass index, kg/m2 (mean  S.D.) 23.3  3.7
Age at onset, years (mean  S.D.) 17.8  12.3
Epilepsy duration, years (mean  S.D.) 17.4  9.5
Weekly partial seizure frequency
Mean  S.D. 0.82  0.57
Median 0.62
Interquartile range (Q1—Q3) 0.39—1.09
Min—max 0.23—2.49
No. of previous antiepileptic drugs (AEDs). n (%)
0 11 (11%)
1 13 (13%)
2 21 (21%)
3 17 (17%)
4 14 (14%)
5 24 (24%)
Previous AEDs, n (%)
Valproic acid 44 (44%)
Topiramate 36 (36%)
Carbamazepine 36 (36%)
Phenytoin 35 (35%)
Lamotrigine 31 (31%)
Phenobarbital 25 (25%)
Vigabatrin 23 (23%)
No. of concomitant AEDs n (%)
1 14 (14%)
2 80 (80%)
3b 6 (6%)
Most common concomitant AEDs, n (%)
Carbamazepine 53 (53%)
Valproic acid 42 (42%)
Lamotrigine 25 (25%)
Topiramate 25 (25%)
a One patient was 17-year-old but the data was includedthe 16-week treatment period, data up to with-
drawal were used in the analysis of efficacy.
Other variables included global evaluation of
disease evolution and quality of life. A validated
Korean version of the original Quality of Life in
Epilepsy Questionnaire (QOLIE-31) instrument18,19
was filled in at the selection visit and at the end
of the 16-week treatment period or upon early
withdrawal. Following the completion of treatment,
the investigator provided a global evaluation scale
(GES) to assess the overall change in the severity of
the patient’s illness compared to the start of study
medication. The rating was based on overall clinical
impression (marked improvement, moderate
improvement, slight improvement, no change,
slight worsening, moderate worsening, and marked
worsening). Safety was assessed by AEs, physical and
neurological examination, and laboratory evalua-
tion at visit 1 (week 0) and visit 5 (week 16). Physical
examinations included measurement of vital signs
and an electrocardiogram (ECG). The analyses were
done on the ITT population.
Statistical methods
Safety analyses were performed on the intent-to-
treat (ITT) population, which included all patients
who took at least one dose of LEV. However, three
patients who discontinued the study at the early
stage without any post-treatment seizure count did
not contribute into the efficacy analyses based on
seizure count during the treatment period. Study
variables were summarized by descriptive statistics:
mean, median, standard deviation, Q1 and Q3,
range for continuous variables and frequency tables
for categorical variables. Baseline characteristics
(gender, age, aetiology of epilepsy, history of epi-
lepsy, previous and concomitant AEDs) and LEV
exposure were summarized descriptively for the
ITT population.until she was withdrawn from the study.
b Six patients who were regarded as receiving two AEDs plus
benzodiazepines used as an anxiolytic (classified as a third AED
in this protocol), were included in the study.Results
Demographics
A total of 100 patients were enrolled and formed the
ITT population (Table 1). Of these, 52 (52.0%) were
male and 48 (48.0%) were female. Patients’ ages
ranged from 17 to 72 years, with a mean age (S.D.)
of 35.3 (11.7) years. All patients were Korean. The
mean age (S.D.) at onset of epilepsy was 17.8
(12.3) years and the mean duration (S.D.) of
epilepsy was 17.4 (9.5) years. The aetiology of
epilepsy was unknown in 49% of patients or attrib-
uted to cerebral infection (14%), hippocampalsclerosis without a history of significant brain insult
(13%), cranial trauma (8%), malformation of cortical
development (4%), atrophic change including cere-
bromalacia or cyst without a history of significant
brain insult (4%), cavernous haemangioma (2%),
cerebral neoplasm (2%), cerebral infarction (1%),
brain surgery (1%), perinatal hypoxia (1%), and
tuberous sclerosis (1%). The median (Q1—Q3) base-
line seizure frequency was 0.62 (0.39—1.09) per
week. Eighty patients presented with at least one
complex partial seizure, 28 patients with at least 1
406 K. Heo et al.
Figure 2 Median weekly frequency of seizure.secondarily generalized tonic—clonic seizure, and
13 patients with at least 1 simple partial seizure
during the baseline 3-month period. In the history of
previous AED treatment, 76 patients had taken two
or more AEDs prior to entry to this study. The
majority (80%) of patients entered the trial on
two concomitant AEDs. Six patients were receiving
two AEDs plus benzodiazepines used as anxiolytics
(classified as a third AED in this protocol); these
patients were included in the study because anxio-
lytics were not considered to affect the study result.
The most frequently used concomitant AEDs were
carbamazepine, valproic acid, lamotrigine, and
topiramate.
Of the 100 patients, 92 (92.0%) completed the 16-
week treatment and 8 discontinued the study. Four
patients withdrew due to an AE, one withdrew
because of a lack of efficacy, and three withdrew
for other reasons (withdrawal of consent in two and
violation of inclusion criteria in one). The trial began
on March 5, 2004 and finished on October 6, 2004.
The 100 patients who took one or more doses of
LEV received the treatment for a mean duration
(S.D.) of 105.7 (24.4) days within the study
period. The mean daily dose (S.D.) of LEV during
the 16-week treatment period was 1953 (570) mg,
with amedian daily dose of 2000 mg/day. Mean daily
dose (S.D.) of exposure over the last 8 weeks of
individual titration period for subjects completing
the study (down-titration period excluded) was 2236
(679) mg.
Efficacy
As three patients discontinued the study (withdra-
wal of consent in two patients and AE in one patient)
without providing any seizure count after baseline,
they did not contribute into the efficacy analysis.
Ninety-seven patients were analysed. Overall, 72
patients (74%) experienced a reduction from base-
line in seizure frequency per week throughout the
study period. In the ITT population, the median
(Q1—Q3) percent reduction in seizure frequency
was 43.2% (Q1—Q3, 0.4—84.8%) over the entire
treatment period (range, 812.5 to 100.0%). The
frequency of seizures decreased from a median
(Q1—Q3) of 0.62 (Q1—Q3: 0.39—1.09) per week over
the baseline period to 0.36 (Q1—Q3: 0.06—0.79) per
week over treatment period in the study. The
decrease in median seizure frequency was already
apparent following the initial 2 weeks of titration,
when all patients received 1000 mg/day, and was
maintained throughout the treatment phase. The
median seizure frequency was 0.00 per week during
the initial 2 weeks (n = 96, median reduction from
baseline = 100%), remained at 0.00 per week duringweek 2—4 (n = 96, median reduction from base-
line = 100%), then was 0.33 per week during week
4—10 (n = 96, median reduction from base-
line = 48.33%) and remained at 0.33 during the last
6 weeks (n = 92, median reduction from base-
line = 50.18%) as shown in Fig. 2.
Over the entire treatment period, 45.4% (44/97)
of patients had a 50% or greater reduction in sei-
zures count, 36.1% (35/97) had at least a 75% reduc-
tion, and 18.6% (18/97) of patients had a 100%
reduction; seizure freedom was obtained only for
4 weeks in 1 patient who was found to have a brain
tumour during the trial and discontinued the trial.
During the last 12 weeks, 49.5% (48/97) of patients
had a 50% or greater reduction, 34.0% (33/97) had a
75% or greater reduction, and 22.7% (22/97) of
patients had a 100% reduction.
At V4 (week 10) the LEV dose was increased up to
3000 mg in 13 patients because of insufficient sei-
zure control; 2 patients had a 75% or greater reduc-
tion and a reduction of 50% or greater but less than
75%, respectively and the remaining 11 patients had
less than 50% reduction over the 16-week treat-
ment.
Global evaluation scale and QOLIE-31 (ITT
population)
Improvement (marked, 41%; moderate, 16%; slight,
24%) reported by the investigator was observed in
81% of patients, no change in 16%, and worsening
(slight) in 3%. No cases of moderate or marked
worsening of the disease were reported by investi-
gators. All QOLIE-31 scales, the total score, and
health status item improved. Statistically signifi-
cant changes were reached for all but energy/fati-
gue and medication effects (Table 2). Of the 95
patients evaluable for quality of life analysis, 66
(69.5%) experienced improvement in their overall
QOLIE-31.
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Table 2 Mean QOLIE-31 changes
Domain/item N Baseline mean (S.D.) Change mean (S.D.) p Value
Seizure worry 96 42.0 (25.8) 13.1 (23.5) <0.0001
Overall QOL 96 50.7 (17.1) 4.9 (17.4) 0.0068
Emotional well-being 96 51.2 (18.4) 6.3 (18.2) 0.0010
Energy/fatigue 96 46.3 (19.5) 0.6 (20.9) 0.7822
Cognitive functioning 95 53.4 (24.1) 7.2 (20.2) 0.0008
Medication effects 96 48.2 (30.2) 6.1 (31.8) 0.0622
Social function 96 50.9 (25.7) 7.9 (27.3) 0.0053
Health status 94 53.9 (21.9) 5.0 (22.5) 0.0335
Total score 95 50.0 (17.3) 6.8 (14.5) <0.0001Safety
One hundred and thirteen treatment-emergent AEs
were reported in 59 patients. AEs that emerged in
3% or more of patients during the treatment period
are listed in Table 3. The three most commonly
reported AEs were somnolence (36%), dizziness
(12%), and headache (8%). The majority (96%) of
treatment-emergent AEs were mild to moderate in
intensity. Nine patients reported AEs leading to
temporary discontinuation or dose modification of
LEV. Four patients discontinued the trial due to AEs;
three patients had AEs that were considered by the
investigator to be related to LEV treatment (som-
nolence, headache, and abdominal pain, each in
one subject) and one patient was diagnosed as
having brain tumour during the trial, that was not
considered to be related to LEV treatment. Four
patients experienced serious AEs (brain tumour,
abnormal behaviour, back pain due to traffic acci-
dent, and inguinal hernia). Among them, there was a
patient with abnormal behaviour which was consid-
ered to be related to LEV, leading to temporary
discontinuation of LEV. The other serious AEs were
not considered to be related to LEV treatment.
Psychiatric AEs occurred in five patients (abnormal
behaviour and insomnia, anxiety, and nervousness,
respectively, in three individual patients, and
depression in two patients).Table 3 Treatment-emergent adverse events occur-
ring in 3% or more of enrolled patients (intent-to-treat
population)
Adverse event N (%)
Somnolence 36 (36%)
Dizziness 12 (12%)
Headache 8 (8%)
Fatigue 7 (7%)
Psychiatric disorders 5 (5%)
Diarrhoea 4 (4%)
Asthenia 3 (3%)Neurological examination revealed nervous sys-
tem abnormalities in 10% of patients at baseline
and no relevant change was observed overall during
treatment, with the exception of one subject who
developed slight right hemiparesis due to a brain
tumour. Body weight increases of at least 7% from
baseline occurred in five patients (range >4 to
>10 kg; representing a weight increase of 7.1—
18.0% from baseline), and decreases of at least 7%
occurred in another 10 patients (range4 to10 kg;
representing a weight decrease of 7.0 to 15.3%
from baseline). Three patients had a weight increase
larger than 10% and 3 patients had a weight decrease
larger than 10%. For only one patient showing
decrease, weight change was reported as an AE.
During the course of the 16-week treatment, no
clinically significant changes were observed on ECG,
and minimal changes were observed in the vital
signs. Abnormal blood pressure (BP) was reported
in five patients. Diastolic BP decreased in two
patients, systolic BP decreased in one patient,
and both systolic and diastolic BP decreased in
two patients having possibly clinical significant
(PCS) values (systolic BP,90 mm Hg and a decrease
from baseline of 30 mm Hg; diastolic BP, 50 mm
Hg and a decrease from baseline of 20 mm Hg).
PCS abnormalities in laboratory values were
observed in 18 patients. However, in 10 patients,
these abnormalities were already present at base-
line. The remaining 8 patients had 10 treatment-
emergent PCS abnormalities not present at base-
line: decreased estimated creatinine clearance in 3
patients, decreased haematocrit in 3 patients, and
decreased haemoglobin, white blood cells and
serum glucose, and increased eosinophils in 4 indi-
vidual patients.Discussion
This multicentre open-label study with levetirace-
tam was designed to bridge with a similar study on
Caucasian epileptic subjects20 before authorization
408 K. Heo et al.in Korea. The design of this study was similar to a
post-marketing, open-label, add-on study in
patients with inadequately controlled partial-onset
seizures that was conducted in 1030 patients from
over 300 neurological practices in the US (The KEE-
PERTM trial8). However, the present study was more
similar to community-based clinical practice in that
AED doses could be increased with more flexibility
and patients with less severe epilepsy (low baseline
seizure frequency) were recruited. The median
baseline seizure frequency in this study was 0.62
per week which was less than in other multicentre,
short-term, open-label, single-arm, add-on trials of
similar methodology (3.7 per month in the KEEPERTM
trial,8 2.25 per week in a study by Abou-Khalil et al.9
and 2.3 per week in a study by Beran et al.10).
Similarly to other open-label, short-term trials,
the results of the Korean open-label trial confirm the
results derived from placebo-controlled, blinded
clinical trials.8—10 In the 16-week treatment, LEV
reduced the weekly frequency of seizures by a
median of 43.2%. A total of 72 patients (74%) experi-
enced a reduction from baseline in seizure count; 17
patients became seizure-free from the first day and
remained so throughout the 16-week of treatment
period, 45.4% of patients experienced a reduction in
seizures of50% and 36.1% had a reduction of 75% or
greater.
The decrease in seizures was also reflected in
subjective measures of improvement in the present
study. The global evaluation scale showed disease
improvement in 81% of patients as determined by
the investigator with an overall improvement in
health-related quality of life reported in almost
70% of patients.
This study also provides support for LEV’s safety
confirming the known good safety profile. One hun-
dred and thirteen treatment-emergent AEs were
reported in 59 patients but only four patients were
withdrawn due to AEs (three related to LEV treat-
ment). The withdrawal rate due to AEs in this study
is lower compared with those of the pooled data
from double-blind, placebo-controlled studies21 and
of two trials8,9 of similar methodology (8—13%) but
comparable to those of another trial10 of similar
methodology (2%) and a placebo-controlled trial22
performed in Taiwanese patients (6%).
The commonly reported AEs were somnolence,
dizziness, headache and fatigue. A higher inci-
dence of somnolence was observed in the present
study compared with reports of somnolence in the
pooled data from double-blind, placebo-controlled
studies21 (36% versus 15%), while a lower incidence
of fatigue and headache were reported (7% versus
15% and 8% versus 14%, respectively). The rates of
dizziness (12% versus 9%) were comparable. Theincidence of somnolence in this study was also
much higher in comparison with that in the three
open-label, short-term, trials (11—21%)8—10 but
agrees with that (40%) of a placebo-controlled trial
performed in Taiwanese patients, that used LEV of
up to 2000 mg per day but allowed one to three
concomitant AEDs.22 The Taiwanese study sug-
gested that the high incidence of somnolence
might be related to the greater number of con-
comitant AEDs. In this study, it might be related to
the use of relatively higher doses of LEV in Oriental
patients with lower body weight compared with
Western patients. However, this study showed
lower or similar frequencies in fatigue, headache,
and dizziness that are generally known to be dose-
dependant with most AEDs. Therefore racial dif-
ference might affect the incidence of somnolence.
Experience with LEV therapy in a larger number of
Oriental patients will be necessary to understand
this difference.
This study demonstrated that LEV is effective and
well tolerated in adult Korean subjects with uncon-
trolled partial epilepsy when administered at opti-
mized doses ranging from 1000 to 3000 mg/day, as
evidenced by the high seizure free and retention
rates. The results of this study are also consistent
with those reported in Phase III controlled studies
and other open-label, single-arm trials.Conclusions
LEV administered as adjunctive therapy in Korean
adults with refractory partial epilepsy was effective
and generally well-tolerated, as evidenced by the
high seizure free and retention rates in the 16-week
treatment.Acknowledgment
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